What do Analysts Think About Catalyst Pharmaceuticals (CPRX)?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is one of the best biotech stocks with high potential. HC Wainwright reiterated a Buy rating on Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) on September 17 and set a $35 price target.

Similarly, in a report released on September 11, Jason Gerberry from Bank of America Securities also reiterated a Buy rating on Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) and set a price target of $34.00.

The analyst consensus rating on Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Strong Buy, with the stock’s median price target of $20.71 implying an upside of 64.17% from current levels.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a commercial-stage, biopharmaceutical company involved in the development, in-licensing, and commercialization of novel medicines for patients with difficult-to-treat and rare diseases.

While we acknowledge the potential of CPRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.